AI-Powered Neurology Startup Neu Health Secures €1.9 Million to Expand into the US Market

London-based HealthTech startup Neu Health has raised €1.9 million in funding from Oxford Science Enterprises (OSE) and Cedars-Sinai Intellectual Property Company. The investment will support the company’s expansion beyond the UK as it prepares to enter the US market with its AI-driven neurology care platform.

Founded in 2022 by Caroline Cake and Dr. Kinan Muhammed, Neu Health offers a digital platform designed to improve the management of Parkinson’s disease and dementia. The company’s system leverages AI-based data analytics and real-world patient interactions to provide clinicians with actionable insights. A patient app is integrated with a care team dashboard, enabling the tracking of motor and non-motor symptoms, cognitive function, and mental health indicators in a structured and measurable way.

Neu Health CEO Caroline Cake emphasized that the collaboration with Cedars-Sinai and OSE represents a commitment to enhancing neurology care, stating that their shared goal is to transform what is possible in managing these conditions.

The investment follows Neu Health’s participation in Cedars-Sinai’s 10th Accelerator program, a key initiative that provided the company with access to one of the US’s leading healthcare institutions. As part of its expansion strategy, Neu Health will launch a pilot program at Cedars-Sinai, where 150 patients will test the platform in a six-month trial. The collected data will contribute to refining the platform’s integration into the US healthcare system.

Dr. John Glaser, Chairman of the Board at Neu Health, highlighted the personal significance of this initiative, sharing that neurological diseases have impacted his family. He noted that the company’s technology would help clinicians, patients, and caregivers take significant steps toward better disease management.

This funding marks the first investment under a newly formed partnership between Oxford Science Enterprises and Cedars-Sinai Intellectual Property Company. The collaboration aims to accelerate the entry of Oxford-founded HealthTech startups into the US market by offering clinical and commercial expertise, along with real-world testing opportunities for emerging healthcare technologies.

Heather Roxborough, Senior Partner of Health Tech at Oxford Science Enterprises, stated that working with Cedars-Sinai aligns with their mission to commercialize world-leading research and build innovative companies. She added that the partnership plays a vital role in helping startups navigate the US market by providing critical insights and validation for their healthcare solutions.

With this latest funding and the upcoming pilot program at Cedars-Sinai, Neu Health is advancing its efforts to establish itself as a key player in digital neurology care.